| Identification | Back Directory | [Name]
Belizatinib | [CAS]
1357920-84-3 | [Synonyms]
TSR-011
CS-2493
Belizatinib
Belizatinib (TSR011)
TSR011; TSR011; TSR 011; BELIZATINIB
Benzamide, 4-fluoro-N-[6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-1-[cis-4-[[(1-methylethyl)amino]carbonyl]cyclohexyl]-1H-benzimidazol-2-yl]- | [Molecular Formula]
C33H44FN5O3 | [MDL Number]
MFCD31728490 | [MOL File]
1357920-84-3.mol | [Molecular Weight]
577.73 |
| Chemical Properties | Back Directory | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:30.0(Max Conc. mg/mL);51.93(Max Conc. mM)
DMSO:143.33(Max Conc. mg/mL);248.08(Max Conc. mM)
Ethanol:65.0(Max Conc. mg/mL);112.5(Max Conc. mM) | [form ]
A crystalline solid | [pka]
12.55±0.43(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Belizatinib, also known as TSR-011, is an oral inhibitor of ALK and TRK. | [Uses]
Belizatinib is used in treating diseases via targeted modulation of gene signaling networks. | [in vivo]
Belizatinib (TSR-011) exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1]. | [IC 50]
TrkA; TrkB; TrkC | [storage]
Store at -20°C | [References]
[1] H. ARKENAU. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.[J]. Journal of Clinical Oncology, 2015, 33 1: 8063-8063. DOI: 10.1200/jco.2015.33.15_suppl.8063 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|